Filing Flows › Mangoceuticals (MGRX) › Q2 2025
Mangoceuticals (MGRX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Mangoceuticals (MGRX) reported revenue of $168K for the second quarter 2025 (Q2 2025), +3% from a year earlier and +54% from the quarter before.
Mangoceuticals, Q2 2025: revenue $168K (+3% year over year), net loss $5.4M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $168K | +54% | +3% |
| Operating profit | −$5.3M | — | — |
| Net earnings | −$5.4M | — | — |
| Operating cash flow | −$1.3M | — | — |
What changed
Revenue was $168K in Q2 2025, up 3% year over year and up 54% from the previous quarter.
Gross margin was 53.5%, up 10.7 points from a year earlier. Operating costs exceeded revenue by $5.3M, an operating margin of -3134.0%. Operating expenses grew 139% against revenue growth of 3%. The fastest-growing cost line was Other operating costs (+233%). The quarter ended with a net loss of $5.4M, wider than the previous quarter's $4.8M loss.
Operating cash flow was −$1.3M. Non-cash charges added back $278K of depreciation and amortization and $51K of share-based compensation. Working capital and other items added $3.8M.
Questions
What was Mangoceuticals' revenue in the second quarter 2025?
Mangoceuticals (MGRX) reported revenue of $168K for the second quarter 2025 (Q2 2025), +3% from a year earlier and +54% from the quarter before.
Source: Mangoceuticals 10-Q on SEC EDGAR.